Boston Scientific is having a good run.  Its sales are up and its new drug-eluting stent Taxus, which has been doing well outside the US, is close to approval here.  J&J’s Cypher stent is likely to be the main loser when Taxus is approved here, but the arms race between these two and Guidant will continue.  Of course everyone’s ignoring what the Stanford study said about the value of these stents last year.

Boston Scientific’s stock is up nearly 30% in the last 3 months.